217 related articles for article (PubMed ID: 36889810)
41. Novel adjuvant options for cutaneous melanoma.
Dimitriou F; Long GV; Menzies AM
Ann Oncol; 2021 Jul; 32(7):854-865. PubMed ID: 33771664
[TBL] [Abstract][Full Text] [Related]
42. Adjuvant treatment for melanoma in clinical practice - Trial versus reality.
de Meza MM; Ismail RK; Rauwerdink D; van Not OJ; van Breeschoten J; Blokx WAM; de Boer A; van Dartel M; Hilarius DL; Ellebaek E; Bonenkamp HJ; Blank CU; Aarts MJB; van Akkooi ACJ; van den Berkmortel FWPJ; Boers-Sonderen MJ; de Groot JWB; Haanen JB; Hospers GAP; Kapiteijn EW; Piersma D; van Rijn RS; van der Veldt AAM; Vreugdenhil A; Westgeest HM; van den Eertwegh AJM; Suijkerbuijk KPM; Wouters MWJM
Eur J Cancer; 2021 Nov; 158():234-245. PubMed ID: 34600790
[TBL] [Abstract][Full Text] [Related]
43. Patterns of Recurrence in Patients with Stage IIIB/C Cutaneous Melanoma of the Head and Neck Following Surgery With and Without Adjuvant Radiation Therapy: Is Isolated Regional Recurrence Salvageable?
Barbour S; Mark Smithers B; Allan C; Bayley G; Thomas J; Foote M; Burmeister B; Barbour AP
Ann Surg Oncol; 2015 Nov; 22(12):4052-9. PubMed ID: 25582744
[TBL] [Abstract][Full Text] [Related]
44. Nodal Recurrence is a Primary Driver of Early Relapse for Patients with Sentinel Lymph Node-Positive Melanoma in the Modern Therapeutic Era.
Mitra D; Ologun G; Keung EZ; Goepfert RP; Amaria RN; Ross MI; Gershenwald JE; Lucci A; Fisher SB; Davies MA; Lee JE; Bishop AJ; Farooqi AS; Wargo J; Guadagnolo BA
Ann Surg Oncol; 2021 Jul; 28(7):3480-3489. PubMed ID: 33856603
[TBL] [Abstract][Full Text] [Related]
45. BRAF mutation correlates with worse local-regional control following radiation therapy in patients with stage III melanoma.
Wolfe AR; Chablani P; Siedow MR; Miller ED; Walston S; Kendra KL; Wuthrick E; Williams TM
Radiat Oncol; 2021 Sep; 16(1):181. PubMed ID: 34537078
[TBL] [Abstract][Full Text] [Related]
46. Treatment outcome for synchronous locoregional failures of nasopharyngeal carcinoma.
Chua DT; Wei WI; Sham JS; Cheng AC; Au G
Head Neck; 2003 Jul; 25(7):585-94. PubMed ID: 12808662
[TBL] [Abstract][Full Text] [Related]
47. Treatment of High Risk Resected Melanoma in Australia: Current Landscape and Practises.
Bhave P; Haydon A
Australas J Dermatol; 2020 Aug; 61(3):203-209. PubMed ID: 32403192
[TBL] [Abstract][Full Text] [Related]
48. Adjuvant Sandwich Chemotherapy Plus Radiotherapy vs Adjuvant Chemotherapy Alone for Locally Advanced Bladder Cancer After Radical Cystectomy: A Randomized Phase 2 Trial.
Zaghloul MS; Christodouleas JP; Smith A; Abdallah A; William H; Khaled HM; Hwang WT; Baumann BC
JAMA Surg; 2018 Jan; 153(1):e174591. PubMed ID: 29188298
[TBL] [Abstract][Full Text] [Related]
49. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial.
Long GV; Luke JJ; Khattak MA; de la Cruz Merino L; Del Vecchio M; Rutkowski P; Spagnolo F; Mackiewicz J; Chiarion-Sileni V; Kirkwood JM; Robert C; Grob JJ; de Galitiis F; Schadendorf D; Carlino MS; Mohr P; Dummer R; Gershenwald JE; Yoon CH; Wu XL; Fukunaga-Kalabis M; Krepler C; Eggermont AMM; Ascierto PA;
Lancet Oncol; 2022 Nov; 23(11):1378-1388. PubMed ID: 36265502
[TBL] [Abstract][Full Text] [Related]
50. Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for resected melanoma.
Weber JS; Ascierto PA; Middleton MR; Hennicken D; Zoffoli R; Pieters A; Amadi A; Kupas K; Kotapati S; Moshyk A; Schadendorf D
Eur J Cancer; 2021 Nov; 158():225-233. PubMed ID: 34663559
[TBL] [Abstract][Full Text] [Related]
51. Postsurgical treatment landscape and economic burden of locoregional and distant recurrence in patients with operable nonmetastatic melanoma.
Tarhini A; Ghate SR; Ionescu-Ittu R; Manceur AM; Ndife B; Jacques P; Laliberté F; Nakasato A; Burne R; Duh MS
Melanoma Res; 2018 Dec; 28(6):618-628. PubMed ID: 30216199
[TBL] [Abstract][Full Text] [Related]
52. Clinical review of treatment outcomes and patterns of failure with adjuvant radiotherapy in node-positive malignant melanoma.
Keenan LG; O'Sullivan S; Glynn A; Higgins M; Flavin A; Brennan S
J Med Imaging Radiat Oncol; 2017 Apr; 61(2):258-262. PubMed ID: 27667733
[TBL] [Abstract][Full Text] [Related]
53. An Economic Evaluation of Pembrolizumab Versus Other Adjuvant Treatment Strategies for Resected High-Risk Stage III Melanoma in the USA.
Bensimon AG; Zhou ZY; Jenkins M; Song Y; Gao W; Signorovitch J; Krepler C; Scherrer E; Wang J; Aguiar-Ibáñez R
Clin Drug Investig; 2020 Jul; 40(7):629-643. PubMed ID: 32418051
[TBL] [Abstract][Full Text] [Related]
54. Observation after a positive sentinel lymph node biopsy in patients with melanoma.
Bamboat ZM; Konstantinidis IT; Kuk D; Ariyan CE; Brady MS; Coit DG
Ann Surg Oncol; 2014 Sep; 21(9):3117-23. PubMed ID: 24833100
[TBL] [Abstract][Full Text] [Related]
55. Roles of adjuvant and salvage radiotherapy for desmoplastic melanoma.
Oliver DE; Patel KR; Switchenko J; Parker D; Lawson DH; Delman KA; Kudchadkar RR; Khan MK
Melanoma Res; 2016 Feb; 26(1):35-41. PubMed ID: 26397051
[TBL] [Abstract][Full Text] [Related]
56. Adjuvant Therapy for Stage III Melanoma Without Immediate Completion Lymph Node Dissection.
Torphy RJ; Friedman C; Ho F; Leonard LD; Thieu D; Lewis KD; Medina TM; Robinson WA; Gonzalez RC; Stewart CL; Kounalakis N; McCarter MD; Gleisner A
Ann Surg Oncol; 2022 Feb; 29(2):806-815. PubMed ID: 34537899
[TBL] [Abstract][Full Text] [Related]
57. Axillary treatment for operable primary breast cancer.
Bromham N; Schmidt-Hansen M; Astin M; Hasler E; Reed MW
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD004561. PubMed ID: 28052186
[TBL] [Abstract][Full Text] [Related]
58. Local Adjuvant Treatment with Low-Dose CpG-B Offers Durable Protection against Disease Recurrence in Clinical Stage I-II Melanoma: Data from Two Randomized Phase II Trials.
Koster BD; van den Hout MFCM; Sluijter BJR; Molenkamp BG; Vuylsteke RJCLM; Baars A; van Leeuwen PAM; Scheper RJ; Petrousjka van den Tol M; van den Eertwegh AJM; de Gruijl TD
Clin Cancer Res; 2017 Oct; 23(19):5679-5686. PubMed ID: 28972083
[No Abstract] [Full Text] [Related]
59. Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial.
Coens C; Suciu S; Chiarion-Sileni V; Grob JJ; Dummer R; Wolchok JD; Schmidt H; Hamid O; Robert C; Ascierto PA; Richards JM; Lebbé C; Ferraresi V; Smylie M; Weber JS; Maio M; Bottomley A; Kotapati S; de Pril V; Testori A; Eggermont AMM
Lancet Oncol; 2017 Mar; 18(3):393-403. PubMed ID: 28162999
[TBL] [Abstract][Full Text] [Related]
60. The benefits of adjuvant radiation therapy after therapeutic lymphadenectomy for clinically advanced, high-risk, lymph node-metastatic melanoma.
Agrawal S; Kane JM; Guadagnolo BA; Kraybill WG; Ballo MT
Cancer; 2009 Dec; 115(24):5836-44. PubMed ID: 19701906
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
